[Tuberculosis].
Tuberkulose.
Interferon-γ release tests
Mycobacterium tuberculosis
Tuberculosis therapy
Tuberculosis, multidrug-resistant
Tuberculosis, pulmonary
Journal
Der Internist
ISSN: 1432-1289
Titre abrégé: Internist (Berl)
Pays: Germany
ID NLM: 0264620
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
pubmed:
24
10
2019
medline:
20
11
2019
entrez:
24
10
2019
Statut:
ppublish
Résumé
Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria. The World Health Organization (WHO) estimates that approximately 10 million patients were newly diagnosed with tuberculosis in 2017. Rapid diagnosis relies on a combination of imaging and microbiological, molecular, and, rarely, immunological tests. Genotypic methods enable early diagnosis and allow highly accurate prediction of drug resistance. Phenotypic (culture-based) methods are the diagnostic gold standard. Standard management of patients with pan drug-susceptible pulmonary tuberculosis includes a combination of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months followed by rifampicin and isoniazid for additional 4 months, which leads to cure rates of >80%. With individualized treatment schemes, similar cure rates can be achieved for patients with multidrug-resistant tuberculosis.
Identifiants
pubmed: 31641790
doi: 10.1007/s00108-019-00685-z
pii: 10.1007/s00108-019-00685-z
doi:
Substances chimiques
Antitubercular Agents
0
Pyrazinamide
2KNI5N06TI
Ethambutol
8G167061QZ
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1155-1175Références
Pathog Immun. 2016;1(2):308-329
pubmed: 28217762
N Engl J Med. 2014 Sep 18;371(12):1121-30
pubmed: 25178809
PLoS One. 2013 May 07;8(5):e63057
pubmed: 23667572
Clin Infect Dis. 2007 Sep 15;45(6):715-22
pubmed: 17712755
N Engl J Med. 2015 Nov 26;373(22):2149-60
pubmed: 26605929
Lancet Infect Dis. 2017 Jan;17(1):39-49
pubmed: 28100438
Eur Respir J. 2011 Jan;37(1):100-11
pubmed: 20847080
Int J Antimicrob Agents. 2014 Sep;44(3):229-34
pubmed: 24985091
J Clin Microbiol. 1998 Jun;36(6):1512-7
pubmed: 9620369
Nat Commun. 2017 Sep 19;8(1):588
pubmed: 28928454
Pneumologie. 2017 Jun;71(6):325-397
pubmed: 28651293
Eur Respir J. 2018 May 3;51(5):
pubmed: 29599184
N Engl J Med. 2019 Mar 14;380(11):1001-1011
pubmed: 30865794
Eur Respir J. 2009 May;33(5):956-73
pubmed: 19407047
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455227
Lancet Respir Med. 2019 Mar;7(3):249-259
pubmed: 30630778
N Engl J Med. 2018 Aug 2;379(5):440-453
pubmed: 30067931
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662
pubmed: 31315696
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):93-98
pubmed: 30674380
Int J Tuberc Lung Dis. 2016 Jan;20(1):24-42
pubmed: 26688526
Tuberc Res Treat. 2011;2011:798764
pubmed: 22567269
Lancet. 2019 Apr 20;393(10181):1642-1656
pubmed: 30904262
Clin Infect Dis. 2008 Jul 15;47(2):203-7
pubmed: 18532893
N Engl J Med. 2018 Oct 25;379(17):1621-1634
pubmed: 30280651
Eur Respir J. 2017 Dec 28;50(6):
pubmed: 29284687
N Engl J Med. 2011 Dec 8;365(23):2155-66
pubmed: 22150035